SecSonar.com

Esperion Therapeutics, Inc. (ESPR)

Esperion Therapeutics, Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

Esperion Therapeutics, Inc. (ESPR) is a Biotechnology company based in US with a market capitalization of $650.8M. Revenue grew 21.3% year-over-year and free cash flow was negative at -$13.1M. This page tracks ESPR's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

US · 304 employees · IPO Jun 26, 2013

Valuation

Valuation & price

$3.12 · as of May 17, 2026 · -23.5% vs 52w high

—

P/E ratio

Latest-FY diluted EPS

—

P/B ratio

Market cap ÷ book equity

—

Dividend yield

Price — last 12 months

$4.08$2.60$1.11Jul 25Dec 25Jun 26Jul 7, 25$1.11Jul 9, 25$1.23Jul 11, 25$1.19Jul 15, 25$1.13Jul 17, 25$1.24Jul 21, 25$1.15Jul 23, 25$1.33Jul 25, 25$1.51Jul 29, 25$1.47Jul 31, 25$1.42Aug 4, 25$1.49Aug 6, 25$1.92Aug 8, 25$1.87Aug 12, 25$1.79Aug 14, 25$2.07Aug 18, 25$2.10Aug 20, 25$2.05Aug 22, 25$2.17Aug 27, 25$2.18Aug 29, 25$2.22Sep 3, 25$2.43Sep 5, 25$2.68Sep 9, 25$2.54Sep 11, 25$2.79Sep 15, 25$2.78Sep 17, 25$2.72Sep 19, 25$2.66Sep 23, 25$2.48Sep 25, 25$2.56Sep 29, 25$2.64Oct 1, 25$2.90Oct 3, 25$3.30Oct 7, 25$3.09Oct 9, 25$2.46Oct 13, 25$2.72Oct 16, 25$2.65Oct 20, 25$2.82Oct 22, 25$2.72Oct 24, 25$2.71Oct 28, 25$3.04Oct 30, 25$2.84Nov 3, 25$2.95Nov 5, 25$2.94Nov 7, 25$2.66Nov 11, 25$3.10Nov 13, 25$2.96Nov 17, 25$2.82Nov 19, 25$2.79Nov 21, 25$3.08Nov 25, 25$3.69Nov 28, 25$4.01Dec 2, 25$3.66Dec 5, 25$3.73Dec 9, 25$3.79Dec 11, 25$4.08Dec 15, 25$3.78Dec 17, 25$3.65Dec 19, 25$3.93Dec 23, 25$3.88Dec 26, 25$4.04Dec 30, 25$3.69Jan 2, 26$3.71Jan 6, 26$3.72Jan 8, 26$3.91Jan 12, 26$3.55Jan 14, 26$3.23Jan 16, 26$3.04Jan 21, 26$2.98Jan 23, 26$3.14Jan 28, 26$3.46Jan 30, 26$3.39Feb 3, 26$3.51Feb 5, 26$3.18Feb 9, 26$3.32Feb 11, 26$3.46Feb 13, 26$3.43Feb 18, 26$3.57Feb 20, 26$3.48Feb 24, 26$3.30Feb 26, 26$3.36Mar 2, 26$3.27Mar 4, 26$2.91Mar 6, 26$2.72Mar 10, 26$2.70Mar 12, 26$2.47Mar 16, 26$2.69Mar 19, 26$2.60Mar 23, 26$2.62Mar 25, 26$2.76Mar 27, 26$2.74Mar 31, 26$2.74Apr 2, 26$2.61Apr 7, 26$2.31Apr 9, 26$2.18Apr 13, 26$2.22Apr 15, 26$2.17Apr 17, 26$2.04Apr 21, 26$1.92Apr 23, 26$1.91Apr 27, 26$1.91Apr 29, 26$1.91May 1, 26$3.11May 5, 26$3.12May 8, 26$3.14May 12, 26$3.13May 14, 26$3.12May 18, 26$3.13May 20, 26$3.13May 22, 26$3.13May 27, 26$3.13May 29, 26$3.13Jun 2, 26$3.14Jun 4, 26$3.13Jun 8, 26$3.15Jun 10, 26$3.14Jun 12, 26$3.15Jun 16, 26$3.16Jun 18, 26$3.15Jun 23, 26$3.16Jun 29, 26$3.15
$1.1152-week range$4.08
Loading valuation history…

Fundamentals

Key fundamentals

$650.8M

Market cap

21.3%

Revenue growth (YoY)

68.0%

Gross margin

-$13.1M

Free cash flow (USD)

$380.1M

Net debt

11.1%

Share dilution

0/4

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

2016 → 2025

FY 2016$0.00FY 2017$0.00FY 2018$184.5MFY 2019$148.4MFY 2020$227.5MFY 2021$78.4MFY 2022$75.5MFY 2023$116.3MFY 2024$332.3MFY 2025$403.1M
$0$403.1M

Free cash flow by year

2016 → 2025

FY 2016$-47.8MFY 2017$-131.3MFY 2018$-148.8MFY 2019$-71.3MFY 2020$-98.5MFY 2021$-263.8MFY 2022$-174.8MFY 2023$-135.5MFY 2024$-24.0MFY 2025$-13.1M
-$47.8M-$13.1M

Gross margin by year

2021 → 2025

FY 202181.9%FY 202264.3%FY 202362.8%FY 202479.4%FY 202568.0%
81.9%68.0%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

0

Insider buys · 90 days

3

Insider sells · 90 days

Earnings

Last report: 10-Q filed May 8, 2026

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • Insider sellInsider Sell $34KHalladay Benjamin · Chief Financial Officer · $34KJun 18, 2026Filing
  • Insider sellInsider Sell $169KKoenig Sheldon L. · Director, President and CEO · $169.1KJun 18, 2026Filing
  • Insider sellInsider Sell $37KLooker Benjamin · Chief Legal Officer · $37.3KJun 18, 2026Filing
  • 8-K eventAcquisition CompletedJun 18, 2026Filing
  • 8-K eventMerger Agreement UpdateJun 16, 2026Filing
  • 8-K eventMerger ClearanceJun 9, 2026Filing
  • 8-K eventStock Option Plan EstablishedJun 1, 2026Filing
  • Quarterly report10-Q FiledMay 8, 2026Filing
  • 8-K eventMerger AgreementMay 1, 2026Filing
  • 8-K eventCredit Agreement AmendmentApr 2, 2026Filing

Questions

Frequently asked questions

What is Esperion Therapeutics, Inc.'s market cap?

Esperion Therapeutics, Inc. (ESPR) has a market capitalization of $650.8M.

What is ESPR's P/E ratio?

A meaningful P/E ratio is not available for ESPR — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.

Are insiders buying ESPR stock?

SEC Form 4 filings show no open-market insider buys at Esperion Therapeutics, Inc. in the last 90 days (3 sells).

Same arena

Related companies in Biotechnology

ANL

Adlai Nortye Ltd.

$652.4M

BIOA

BioAge Labs, Inc.

$646.1M

CRMD

CorMedix Inc.

$659.8M

PRME

Prime Medicine, Inc.

$632.2M

DNA

Ginkgo Bioworks Holdings, Inc.

$628.4M

PROK

ProKidney Corp.

$621.5M

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.